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Abstract
Background: Most studies on health-related quality of life (HRQOL) in children with cancer
focussed on survivors. Only few studies have evaluated patients during ongoing oncological
treatment. The aim of this study was a prospective assessment of HRQOL in children during the
first year after diagnosis of cancer and an examination of demographic, medical, and parental
predictors of HRQOL.
Methods: Fifty-two patients (mean age: 10.9 years) were assessed 6 weeks and 1 year after
diagnosis with the TNO-AZL Questionnaire for Children's Health-Related Quality of Life. Parents
completed the Brief Symptom Inventory.
Results: Compared to a community sample, patients reported more physical complaints, reduced
motor functioning and autonomy, and impaired positive emotional functioning 6 weeks after
diagnosis. HRQOL significantly improved over the year. However, at 1 year, patients still showed
reduced motor and emotional functioning. At 6 weeks, children with leukemia were most affected.
At 1 year, patients with brain tumors complained about more physical symptoms than the other
groups. Intensity of treatment and presence of medical complications mainly influenced HRQOL at
6 weeks but less at 1 year. Parental psychopathology was associated with better cognitive
functioning in the child.
Conclusion: This prospective study found several domains of HRQOL to be compromised 6
weeks and 1 year after the diagnosis of cancer. Although HRQOL significantly increased over the
year, there were important differences between diagnostic groups. The findings highlight the
importance of repeated evaluation of HRQOL in children undergoing cancer treatment and
consideration of specific differences between diagnostic groups.
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Background
There has been a dramatic improvement in long-term sur-
vival of childhood cancer patients during the past dec-
ades. This is related to new approaches to treatment,
centralization of care, improved supportive care, and the
development of large international clinical trials. Tradi-
tionally, progress in pediatric oncology has been meas-
ured in terms of survival and rates of response to
treatment. Five-year survival rates are now approaching
70% for children with brain tumors and are exceeding
80% for patients with acute lymphoblastic leukemia [1].
However, the same treatments leading to increased sur-
vival rates can also cause potentially debilitating physical
deficits, such as endocrine dysfunction, neuropsychologi-
cal deficits or subsequent malignancies. While survival
rates and health status are fairly easy to assess, they often
do not appropriately mirror the entire impact of the can-
cer and its treatment on the individual child, particularly
with respect to subjective experiences. Such consequences
of disease and treatment can be tapped by measures of
health-related quality of life (HRQOL). HRQOL is
defined as a multidimensional construct composed of the
patient's perception of the impact of disease and treat-
ment on his or her functioning in a variety of aspects of
life, including the physical, psychological and social
domains [2,3]. In children, HRQOL is usually assessed by
patients' self report or by parental proxy report.
In the past years there has been an increasing interest in
studying HRQOL in pediatric cancer patients. Most stud-
ies focussed on survivors and found significant impair-
ment in HRQOL [2,4-6]. Specifically, survivors of CNS
tumors seem to be at high risk [5-7]. However, findings
are inconsistent and there are also studies that found sur-
vivors to have entirely normal HRQOL [8,9]. These incon-
sistencies can be explained by small sample sizes, wide
age range of the children studied, and great variation with
regard to type of cancer, treatment, and time elapsed since
diagnosis.
Only a few studies have been conducted with pediatric
cancer patients during the acute phase of the disease, i.e.,
during ongoing oncological treatment. Taken together,
these studies suggest that HRQOL in children during ther-
apy is significantly lower than in survivors that have com-
pleted treatment and in the normal population,
respectively [5,9,10]. Also, Magal-Vardi et al. [11] found
an association between intensity of treatment and child-
reported HRQOL: high-risk children reported poorer
quality of life than children with a low or moderate risk.
In a recent study, Eiser et al. [12] assessed maternal reports
of HRQOL of children with acute lymphoblastic leukemia
at 3–6 months and at one year after diagnosis. The authors
found a significant improvement of HRQOL scores during
the first year after diagnosis. However, some limitations of
these studies in acutely ill children merit note. First, med-
ical and psychosocial predictors of HRQOL in acutely ill
children have not been studied in detail in a prospective
design. Notably, Magal-Vardi et al. [11] used a prospective
design, but their sample of 20 children was to small to sys-
tematically analyze predictors of HRQOL. Second, most
studies of acutely ill children used proxy reports of the
child's HRQOL and did not assess the subjective perspec-
tive of the individual child [5,10,12].
The aim of the present study was a comprehensive stand-
ardized evaluation of self-reported HRQOL in children
and adolescents during the first year after a new diagnosis
of cancer and a comparison to healthy children. Based on
the findings cited above, we hypothesized that children
and adolescents with cancer would show a reduced
HRQOL during the most acute phase of treatment with
improvement over the first year of treatment. Further-
more, we aimed at examining the extent to which sociode-
mographic, illness-, treatment- and parental
characteristics were associated with HRQOL. Children
with a higher intensity of medical treatment and more
medical complications and children with maladjusted
parents were expected to have a reduced HRQOL.
Methods
Sample and procedure
The study was approved by the Institutional Review
Boards of all study sites. Patients were consecutively
assessed over a period of 36 months at four children's hos-
pitals in the German speaking part of Switzerland. The
patients and their parents were approached about two
weeks after diagnosis if the following criteria were met: 1)
new diagnosis of cancer; 2) age between 6.5 and 15 years;
3) no major illness other than cancer; 4) sufficient com-
mand of the German language; 5) no evidence of prior
mental retardation (physician's rating). Families received
written and verbal information about the study and were
requested to give signed consent.
Of 83 patients who met these criteria, 22 (10 girls, 12
boys; mean age = 10.43 years) did not participate, mainly
because the study seemed too time consuming or because
the family felt overwhelmed, leaving 61 patients. Due to
incomplete data at either of the two assessments, 9 chil-
dren (of which three died between the assessments) were
excluded from further analyses. The final sample com-
prised 52 children (response rate 63%). Response rate in
parents of the selected children was lower, with 48 moth-
ers and 41 fathers filling in the questionnaires. There were
no significant differences between study completers and
those who did not participate or had incomplete data with
regard to age (t = -1.03; df = 81; p = .31), sex (χ2 = 0.10; df
= 1; p = .76), and medical diagnosis (χ2 = 3.40; df = 3; p =
.33) of the child. Non-participants had the following diag-Health and Quality of Life Outcomes 2006, 4:63 http://www.hqlo.com/content/4/1/63
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noses: leukemia 51.9%, lymphoma 36.5%, brain tumors
13.5%, other solid tumors 17.3%.
Assessments were carried out 6 weeks (T1) and 1 year (T2)
after diagnosis. The children were assessed by means of a
standardised face-to-face interview lasting from 30 to 45
minutes conducted by trained graduate students of psy-
chology. To ensure that children could express their own
feelings and opinions openly, they were interviewed if
possible without their parents being present. Parents
received their questionnaires at the same time and were
asked to complete them separately. Information on
demographic and basic medical variables was retrieved
from the patients' hospital records. Data on course of
treatment and functional status of the child were assessed
by questionnaire from the pediatric oncologist in charge
of treatment.
Measures
Health-related quality of life
Child HRQOL was assessed with the authorized German
version of a short form of the TNO-AZL Children's Qual-
ity of Life (TACQOL) questionnaire [13]. The TACQOL is
a generic instrument designed for HRQOL assessment in
medical research and clinical trials. It contains five health
status scales: physical functioning, basic motor function-
ing, autonomy, cognitive and social functioning. In addi-
tion, two scales assess general mood: Positive emotional
functioning and negative emotional functioning. Follow-
ing the TACQOL protocol, children were first asked
whether a specific problem or symptom had occurred dur-
ing the two weeks prior to the interview. If affirmed, the
child was requested to rate his or her emotional response
to the problem on a 4-point Likert-scale. Higher scores
represent a better HRQOL. The short form included the
original seven scales, but used only four items per scale
instead of eight for all scales except one (physical func-
tioning). The short form of the TACQOL was provided
from the original authors by using data from the Dutch
reference study [13]. By means of a series of reliability
analyses the original authors determined which items
could be removed from each separate scale with a mini-
mum of loss of scale homogeneity. Following this, a prin-
cipal component analysis was performed to assess the
scale structure of the remaining items. The results sup-
ported an internal and external validity of the short form
that is comparable to the original TACQOL. Cronbach's
alphas of the subscales in the reference sample were
between .66 and .77. Norms for this study are provided
from a community sample of 1'048 Dutch children [13].
Parental psychological adjustment
Six weeks after the child's diagnosis mothers and fathers
were assessed with the Brief Symptom Inventory (BSI), a
53-item self-report measure assessing the presence and
intensity of psychopathological symptoms in adults [14].
The German version of the BSI has been shown to have
good reliability and validity [15]. In this study the Global
Severity Index (GSI) was used as an overall measure of
psychopathology.
Intensity of oncological treatment
The responsible pediatric oncologist rated treatment
intensity on a 3-point scale, with 1 = low: surgery only or
six months chemotherapy only or both, with a favorable
prognosis (e.g., Hodgkin disease); 2 = medium: treatment
longer than 6 months according to the treatment proto-
col, with an intermediate prognosis (e.g., osteosarcoma);
3 = high: treatment according to high risk protocols, bone
marrow transplantation, with a infavorable prognosis
(e.g., high-risk leukemia). A very similar scale has success-
fully been used in a previous study by Magal-Vardi et al.
(11).
Medical complications
The pediatric oncologist in charge was asked to rate med-
ical complications in each patient at 6 weeks and 1 year
using a 3-point Likert severity scale: 0 = no complications;
1 = moderate complications (e.g., hospitalization due to
infection), 2 = severe complications (e.g., multiple hospi-
talizations due to infections, no response to treatment).
Child functional status
Information on functional status with regard to physical
activities of daily life was obtained from the pediatric
oncologists. They were asked to rate the functional status
of patients at 6 weeks and 1 year using a 3-point Likert
severity scale: 0 = good functional status, 1 = moderate
functional status, 2 = poor functional status. In order to
increase interrater reliability, the different degrees of func-
tional impairment were defined in the questionnaire. This
measure has successfully been used in an earlier study in
children with a chronic disease [16].
Socioeconomic status
Socioeconomic status (SES) was calculated by means of a
score reflecting paternal occupation and maternal educa-
tion (range 2–12 points). Three social classes were defined
as follows: scores 2–5, lower class; scores 6–8, middle
class; scores 9–12, upper class. This measure has been
shown to be a reliable and valid indicator of SES in our
community [17].
Statistical analyses
Descriptive statistics (means, SD, and frequencies) were
calculated for all variables. Differences between the
patients and the reference group on HRQOL measures
were examined using one-sample Student's t-tests. Other-
wise, non-parametric statistical techniques were used
where possible (Wilcoxon tests for pair-wise comparisonsHealth and Quality of Life Outcomes 2006, 4:63 http://www.hqlo.com/content/4/1/63
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over time, Kruskal-Wallis tests for multiple group compar-
isons, Spearman-Brown rank correlations to calculate
associations), because most of the TACQOL scales
showed non-normal distributions. All analyses were per-
formed with two-sided tests and a value of p < .05 was
considered significant. Analyses were conducted using
SPSS version 10 for Macintosh (SPSS Inc., Chicago, IL,
USA).
Results
Sample characteristics
Descriptive information about the sample is contained in
Table 1. Sex of patients was not equally distributed, with
more boys taking part in the study. This is consistent with
findings of several international cancer registries [18].
Most families were from the upper- or middle-class, prob-
ably due to the language requirement (many non-Swiss
nationals are from the lower class). A majority of children
suffered from leukemia or malignant lymphoma. How-
ever, about 30 percent of the patients were diagnosed with
a malignant brain tumor or another malignant solid
tumor. The distribution of cancer diagnoses in this sample
is similar to that of all newly diagnosed patients in Swit-
zerland aged 6–15 years [18]. Treatment intensity was
medium to high in over 80% of the sample. One year after
diagnosis, fifty children (96%) had been treated with
chemotherapy, 16 (31%) had had surgical interventions,
and 18 (35%) had received a radiation therapy. Two chil-
dren had been treated with a bone-marrow transplanta-
tion. One year after diagnosis two children (4%) had had
a relapse of the cancer. The average cumulative length of
hospital stay was 15.7 days at T1, and 50.2 days at T2. As
Table 1 shows, about 56% of the patients had experienced
some medical complications in the first 6 weeks after diag-
nosis. At 1 year the rate of complications was almost 70%.
Functional status was rated as being good in only six chil-
dren (12%) after six weeks, but in 32 children (62%) after
one year.
Quality of life at 6 weeks and 1 year
Table 2 shows the mean TACQOL scores at 6 weeks and
one year for the entire group and broken down by diag-
noses, as well as the means of a community sample. Com-
parisons with the reference group reveal that the entire
sample reported a significantly lower HRQOL in several
domains. Specifically, at 6 weeks, the patients reported
more physical complaints, reduced basic motor function-
ing and autonomy, and impaired global positive emo-
tional functioning. At one year, motor functioning and
positive emotional functioning were still significantly
reduced. However, compared to norms, patients now had
significantly less physical complaints. Notably, at both
assessments, the patients' cognitive and social functioning
was normal. Also, the level of negative emotions was not
increased in patients.
Comparisons between diagnostic groups with regard to
HRQOL revealed that children with leukemia reported
significantly more physical symptoms at 6 weeks than
children with brain tumors. Motor functioning was also
more impaired in patients with leukemia. However, due
to the small sample size this difference did not reach sta-
tistical significance. At one year, comparisons of diagnos-
tic groups revealed no significant differences. Yet, there
was an interesting tendency showing that patients with
brain tumors now complained about more physical
symptoms than the other diagnostic groups.
Table 2 also shows positive changes in HRQOL in the
entire sample between 6 weeks and one year after diagno-
sis with regard to physical symptoms, motor functioning,
autonomy, and positive emotional functioning. Interest-
ingly, cognitive and social functioning and the presence of
Table 1: Demographic and medical characteristics of the sample 
(n = 52)
Age at diagnosis (years)
Mean (SD) 10.93 (2.62)
Median 10.63
Sex
Female 20 (38.5%)
Male 32 (61.5%)
Socioeconomic Status
Lower 3 (5.8%)
Middle 38 (73.1%)
Upper 9 (17.3%)
Unknown 2 (3.8%)
Living with both biological parents 37 (71.2%)
Medical diagnosis
Leukemia 17 (32.7%)
Malignant lymphoma 19 (36.5%)
Malignant brain tumor 7 (13.5%)
Other malignant solid tumor 9 (17.3%)
Intensity of therapy
Low 9 (17.3%)
Medium 35 (67.3%)
High 8 (15.4%)
Medical complications at T1
None 23 (44.2%)
Moderate 26 (50.0%)
Severe 3 (5.8%)
Medical complications at T2
None 16 (32.7%)
Moderate 31 (59.6%)
Severe 4 (7.7%)
Functional status at T1
Good 6 (11.5%)
Moderate 39 (75%)
Poor 7 (13.5%)
Functional status at T2
Good 32 (61.5%)
Moderate 14 (26.9%)
Poor 4 (7.7%)
Unknown 2 (3.9%)Health and Quality of Life Outcomes 2006, 4:63 http://www.hqlo.com/content/4/1/63
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negative emotions did not change over the course of the
disease. These three scales were well within normal ranges
at both assessments. Comparisons of subgroups reveal
that significant positive changes in HRQOL over time
mainly occur in the leukemia and lymphoma groups
whereas the children with brain tumors showed a
decrease of HRQOL scores.
Correlates of quality of life
Table 3 reveals associations between individual character-
istics of the patients, medical variables, and TACQOL
scales at 6 weeks and one year. At both time points, soci-
oeconomic status was not associated with any dimension
of HRQOL. However, two demographic variables proved
to be important. The age of the child was positively related
to autonomy and social functions at 6 weeks and to lower
positive emotional functioning at one year. Also, the sex
of the child predicted several dimensions of HRQOL at 6
weeks after diagnosis. Girls reported a significantly better
functioning in autonomy whereas boys had a better qual-
ity of life with regard to cognitive and emotional domains.
Interestingly, treatment-related variables, such as intensity
of therapy and presence of medical complications mainly
influenced HRQOL at 6 weeks but not at one year. Specif-
ically, a more intense and complicated treatment was
associated with more physical complaints, more prob-
lems in motor functions and a reduced emotional func-
tioning. One year after diagnosis, treatment intensity was
less important for HRQOL. However, a significant associ-
ation between the one-year complication rate and emo-
tional functioning could be found. Functional status at 6
weeks was related to motor functioning at 6 weeks but to
none of the HRQOL dimensions at one year. A better
functional status at 12 months was associated with better
motor and emotional functioning. Finally, Table 3 also
reveals significant correlations between parental psycho-
logical adjustment at 6 weeks and some of the TACQOL
scales. Children reported significantly less cognitive prob-
lems if their mothers or fathers had higher scores in the
BSI. In addition, paternal psychopathology at 6 weeks was
predictive of higher HRQOL with regard to social func-
tioning in the child. Although the correlations are statisti-
cally not significant, there is a clear tendency for a negative
association of maternal maladjustment with the emo-
tional domains of HRQOL in the acute phase of treat-
ment.
Discussion
This prospective one year follow-up study in children and
adolescents with newly diagnosed cancer found several
domains of HRQOL to be markedly compromised. Nota-
bly, compared to a community sample, children reported
a diminished quality of life in the physical, motor and
emotional domains. In addition, 6 weeks after diagnosis
children reported impaired autonomy. The diminishment
of quality of life was more pronounced 6 weeks after diag-
nosis than at the one year follow-up where HRQOL was
found to be reduced in only two domains. These results
are consistent with our hypothesis and confirm earlier
findings by Eiser et al. [10] on significant improvement of
mother-reported HRQOL in children with leukemia
between a 3–6 months and a one year follow-up. Com-
parisons between children with different types of cancer
in our study revealed that at 6 weeks after diagnosis chil-
dren with leukemia were the most affected in the majority
of dimensions of HRQOL. At one year, however, children
Table 2: Means (SD's) of TACQOL scores at 6 weeks and at 1 year by diagnostic groups
Norms All (n = 52) Leukemia 
(n = 17)
Lymphoma 
(n = 19)
Brain tumors 
(n = 7)
Other solid tumors 
(n = 9)
pk
TACQOL T1
Physical functions 25.3** (5.0) 23.2 (5.3) 20.3 (5.7) 24.4 (4.2) 26.9 (5.0) 22.8 (4.7) .03
Motor functions 14.8*** (2.0) 11.3 (4.3) 8.8 (4.9) 12.3 (4.1) 13.1 (2.9) 12.3 (2.7) .06
Autonomy 15.8*** (0.9) 15.0 (1.5) 14.7 (1.8) 15.4 (1.0) 14.7 (1.1) 14.8 (2.1) .51
Cognitive functions 13.8 (2.6) 14.4 (2.6) 13.6 (3.8) 14.8 (1.5) 15.2 (1.3) 14.3 (2.1) .70
Social functions 14.4 (1.9) 14.4 (2.2) 13.1 (3.3) 14.8 (1.3) 15.3 (0.5) 15.0 (1.0) .35
Positive emotions 7.2*** (1.3) 5.9 (1.9) 5.6 (1.7) 5.8 (2.2) 6.0 (2.0) 6.3 (1.7) .78
Negative emotions 5.6 (1.5) 5.8 (1.7) 5.8 (2.2) 6.0 (1.4) 6.4 (1.3) 4.7 (1.2) .09
TACQOL T2
Physical functions 25.3*** (5.0) 27.4††† (3.8) 27.1†† (3.7) 28.0†† (3.1) 24.3 (4.6) 29.1† (3.8) .08
Motor functions 14.8** (2.0) 13.2† (3.6) 13.1† (4.1) 14.4 (1.9) 12.3 (3.5) 11.3 (5.1) .20
Autonomy 15.8 (0.9) 15.7†† (1.0) 15.4 (1.5) 16.0† (0.0) 15.4 (1.5) 16.0 (0.0) .17
Cognitive functions 13.8 (2.6) 13.6 (2.5) 13.6 (2.8) 13.5 (2.7) 13.9 (2.5) 13.8 (1.9) .99
Social functions 14.4 (1.9) 14.7 (1.5) 14.7† (1.8) 14.8 (1.3) 14.0 (1.5) 14.8 (1.3) .55
Positive emotions 7.2** (1.3) 6.6† (1.5) 6.8† (1.6) 6.8 (1.4) 5.4 (1.4) 6.7 (1.5) .20
Negative emotions 5.6 (1.5) 5.5 (1.6) 5.7 (1.8) 5.8 (1.6) 5.0† (2.1) 4.9 (0.8) .57
Note: Significant differences between sample und healthy reference group: ** p < .01; *** p < .001; Significant differences between T1 and T2: † p < 
.05; †† p < .01; ††† p < .001; k Kruskal-Wallis tests, multiple group comparisonsHealth and Quality of Life Outcomes 2006, 4:63 http://www.hqlo.com/content/4/1/63
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with brain tumors seemed to be the most affected
although the differences between groups were not statisti-
cally significant. This is in line with earlier findings by
Meeske et al. [5] who found patients with brain tumors to
exhibit more problems than patients with leukemia in the
physical, social, psychosocial, and cognitive domains of
HRQOL. Clearly, the various groups of pediatric cancer
patients are differently affected with regard to their
HRQOL. Probably, these differences are due to different
treatment protocols. Typically, children with leukemia
undergoing chemotherapy suffer from significant treat-
ment-related acute toxicity during the initial induction
phase of their treatment protocol. This particular toxicity
is less pronounced for children undergoing treatment pro-
tocols for brain tumors. This is the first prospective study
to show that the most affected diagnostic groups may
change over time. Contrary to the suggestion of Meeske et
al. [5] we cannot support the notion that patients with
leukemia only have minimal changes in HRQOL during
the active treatment. In fact, children with leukemia had
the most significant improvements between 6 weeks and
one year.
This study also analyzed various individual, medical, and
parental correlates of child HRQOL. Consistent with our
hypothesis medical and treatment variables, such as
intensity of therapy and medical complications were asso-
ciated with HRQOL. As can be expected, the influence of
medical variables was more pronounced at 6 weeks than
at one year after diagnosis. Thus, the influence of medical
and treatment variables on HRQOL gets smaller over the
course of treatment which may be due to adjustment
processes and a reduction of treatment intensity. How-
ever, ongoing medical complications and an impaired
functional status still affected emotional domains of
HRQOL in a negative way after one year. Thus, increased
long-term medical problems negatively impact on emo-
tional functioning. Demographic factors such as age and
sex showed particularly strong associations with some
domains of HRQOL at 6 weeks but less at one year. In our
sample, younger children had a higher risk for HRQOL
problems than older children. Also, boys reported fewer
problems in the domains of cognitive and emotional
functioning. The higher vulnerability of girls with regard
to HRQOL problems is well known from other studies
[2,5].
To our knowledge this is the first study to show associa-
tions between parental psychological adjustment and
child self-reported HRQOL in pediatric cancer patients.
These findings are all the more important as different
informants were used for the assessment of parental men-
tal and child HRQOL, respectively, excluding shared
method variance as an explanation. In general, better
parental adjustment was associated with better HRQOL in
the child, particularly in the emotional domain, six weeks
after diagnosis. Surprisingly, however, better maternal
and paternal adjustment were associated with poorer
HRQOL in the child in the cognitive and social domains.
This contradicts previous studies that found family prob-
lems to negatively affect HRQOL in children with chronic
conditions, such as phenylketonuria or nephrotic syn-
drome [17,19]. Certainly, the pathways of parental influ-
ence on the HRQOL of children with chronic health
conditions are not yet well understood and need to be fur-
ther studied in future.
Strengths of this study comprise its use of multiple sources
of information (patients, mothers, fathers, physicians)
and its multidimensional and highly standardized assess-
Table 3: Spearman correlation coefficients between TACQOL scores and sociodemographic, illness-related and parental variables
Age Sex SES Intensity of therapy MC T1 MC T2 FS T1 FS T2 BSI mother T1 BSI father T1
TACQOL T1
Physical functions -.12 -.06 -.26 -.30* -.19 - -.24 - -.15 -.07
Motor functions -.07 -.01 -.08 -.34** -.28* - -.49*** - -.16 -.08
Autonomy .36** .28* .16 .12 -.12 - -.20 - -.01 .01
Cognitive functions -.21 -.33* -.14 -.03 .19 - -.05 - .34* .32*
Social functions .31* -.11 -.16 -.25 .04 - -.13 - .10 -.01
Positive emotions .06 -.02 .17 -.32* -.36** - -.26 - -.26 .14
Negative emotions -.17 -.36** -.26 -.13 -.01 - -.19 - -.23 -.08
TACQOL T2
Physical functions .07 .18 .10 -.01 -.05 -.04 -.14 -.14 .12 .12
Motor functions .01 .13 .17 .05 .10 -.23 -.12 -.36** -.11 .04
Autonomy .24 .08 -.13 .00 -.09 -.24 .01 -.11 .02 -.04
Cognitive functions -.08 -.06 .00 .03 .13 -.13 -.11 -.09 -.02 -.18
Social functions .24 -.08 .06 .17 .20 .02 .18 -.08 .27 .31*
Positive emotions .18 .22 -.07 .11 -.08 -.11 .04 -.24 .06 .23
Negative emotions .42** -.04 -.17 -.20 -.10 -.29* -.11 -.30* -.05 .14
Note: Medical Complications = MC; Functional Status = FS; * p < .05; ** p < .01; *** p < .001Health and Quality of Life Outcomes 2006, 4:63 http://www.hqlo.com/content/4/1/63
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ment of HRQOL in a prospective design. Moreover, sam-
ple patients are representative for newly diagnosed
children aged 6–15 years in Switzerland. Nonetheless,
some limitations merit note. First, our sample is rather
small, making statistically significant findings more diffi-
cult to achieve and limiting comparisons of diagnostic
subgroups. Second, our response rate was only 63%.
Although we compared non-participants and participants
with regard to demographic characteristics and medical
diagnosis we do not know whether these two groups sys-
tematically differed regarding their HRQOL. Third, our
HRQOL instrument is a generic measure not specifically
designed for pediatric cancer. Therefore, it may lack sensi-
tivity for specific problems of this group. However, the
TACQOL has successfully been used in a variety of differ-
ent chronic diseases and has been shown to be a valid and
reliable measure allowing comparison with healthy refer-
ences. Moreover, a German cancer specific HRQOL meas-
ure was only published after this study had been
completed [20]. Fourth, appropriateness of Dutch
HRQOL norms for our sample of Swiss children can be
questioned. However, since the Netherlands and Switzer-
land are European countries with similar social structures,
a major cross-cultural bias seems unlikely. This is con-
firmed by a recent European study in children with
chronic diseases that found HRQOL to be higher in Nor-
dic countries compared to Greece and the UK [21]. How-
ever, children from central European countries such as
Germany and The Netherlands reported very similar
HRQOL. This supports the notion that Dutch norms may
be used for Swiss children. Finally, there may be some
concerns regarding our correlational findings, since the
chance of falsely significant results increases with the
number of comparisons performed on the same set of
data. Because this study had an exploratory character and
the limited sample size did not allow multivariate analy-
ses, subsequent studies are needed to confirm the find-
ings.
Our data suggest some possible issues for future research
activities. First, this study confirmed that the assessment
of HRQOL in children is important and yields valid
results. Hopefully, in the future, HRQOL will be consid-
ered as an important variable in the evaluation of new
medical treatments and standardized HRQOL assessment
will be routinely incorporated into therapeutic cancer tri-
als. HRQOL research can be used to optimize treatment
and to give important information for decision making if
treatment strategies with similar survival rates are com-
pared [22]. Certainly, prospective studies of larger sam-
ples of children undergoing active cancer treatment are
necessary. Repeated assessments will allow analysis of the
course of the disease and the medical, individual and
familial predictors of HRQOL over time, as well as more
detailed comparisons of different oncological groups.
Also, the importance of parental and familial variables on
child HRQOL should be studied in more details because
this may be important for designing appropriate family-
based interventions in children with newly diagnosed
cancer. Probably, findings from studies in pediatric cancer
patients showing the importance of parental variables for
psychological adjustment can be adopted into the
research on HRQOL.
There are some clinical implications that can be drawn
from this study. Our findings confirm the need for
repeated careful evaluation of HRQOL in children who
are undergoing active cancer treatment. Our data show
that there might be significant differences in HRQOL
between diagnostic groups that need to be considered in
psychosocial treatment programs in order to improve
HRQOL in children with cancer. Psychosocial interven-
tions may not only have to be specifically tailored for
diagnostic groups but also for different stages of treat-
ment. Moreover, this study suggests that the whole family
needs to be targeted in order to improve the HRQOL in
children and adolescents with cancer.
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